• metastatic/advanced UC (mUC) - 2nd Line (L2)
• mUC - L2 - all population 2
• mUC - L2 - PDL1 positive 3

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• pembrolizumab based treatment
• pembrolizumab alone

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)

  All patients Age < 65y (younger) Age > 65y Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 > 1% PD-L1 > 10% smoker (Current) smoker (Former) smoker (never)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

mUC - L2 - all population, pembrolizumab alone vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;